Director Shareholding

RNS Number : 0820J

Concepta PLC

26 June 2017

 

26 June 2017

Concepta plc

("Concepta" or the "Company")

Director Shareholding

Concepta plc (AIM:CPT), announces that Erik Henau, Chief Executive Officer of the Company, has  purchased 80,000 Ordinary Shares at a price of 12.175 per share.

Subsequent to this purchase, Erik Henau is interested in 293,333 Ordinary Shares, representing 0.267% of Concepta's issued ordinary share capital.

The notification below is made in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Erik Henau
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Concepta plc
b)	LEI
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.12175 80,000
d)	Aggregated information - Aggregated volume - Price
e)	Date of the transaction	2017-06-22
f)	Place of the transaction	London

Enquiries:

Concepta plc

Adam Reynolds, Chairman

Tel: [phone]

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: [phone]

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: [phone]

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles / Joe Burgess

Tel: [phone]

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.  

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017. The revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

END

 

 

DSHSEEEFIFWSEDM